Miltefosine Disease Interactions
There are 4 disease interactions with miltefosine.
Miltefosine (applies to miltefosine) Sjogren-Larsson syndrome
Major Potential Hazard, High plausibility.
The use of miltefosine is contraindicated in patients with Sjogren-Larsson syndrome. Miltefosine undergoes metabolic cleavage in hepatocytes to release choline. The fatty alcohol-containing fragment of miltefosine is then oxidized to palmitic acid, which enters the metabolism of fatty acids. However, this oxidation is blocked in patients with Sjogren-Larsson syndrome, who have a genetic defect in fatty aldehyde dehydrogenase activity.
References
- (2014) "Product Information. Impavido (miltefosine)." Paladin Therapeutics Inc
Miltefosine (applies to miltefosine) liver disease
Moderate Potential Hazard, High plausibility.
Elevations in liver transaminases (ALT, AST) and bilirubin were observed in clinical trials of miltefosine for the treatment of visceral leishmaniasis. Patients with serum ALT or AST levels at least 3 times the upper limit of normal and bilirubin levels at least 2 times the upper limit of normal were excluded from clinical trials. The pharmacokinetics of miltefosine have not been studied in patients with liver dysfunction; caution is recommended. Liver transaminases (ALT, AST) and bilirubin should be monitored during therapy.
References
- (2014) "Product Information. Impavido (miltefosine)." Paladin Therapeutics Inc
Miltefosine (applies to miltefosine) renal dysfunction
Moderate Potential Hazard, High plausibility. Applicable conditions: Dehydration
Elevations in serum creatinine were observed in clinical trials of miltefosine for the treatment of cutaneous, mucosal, and visceral leishmaniasis. Patients with serum creatinine or BUN levels at least 1.5 times the upper limit of normal were excluded from clinical trials. The pharmacokinetics of miltefosine have not been studied in patients with renal dysfunction; caution is recommended. Renal function should be monitored weekly during therapy and for 4 weeks after completion of therapy. Abdominal pain, nausea, vomiting, and diarrhea are common side effects of miltefosine; patients should be advised to drink plenty of fluids to avoid dehydration (and, thus, the risk of kidney injury) and to seek medical attention if these gastrointestinal side effects are persistent or severe.
References
- (2014) "Product Information. Impavido (miltefosine)." Paladin Therapeutics Inc
Miltefosine (applies to miltefosine) thrombocytopenia
Moderate Potential Hazard, Moderate plausibility.
Thrombocytopenia has been reported during treatment of visceral leishmaniasis, including with miltefosine. Therapy with miltefosine should be administered cautiously in patients with preexisting thrombocytopenia. Platelet counts should be monitored during therapy for visceral leishmaniasis.
References
- (2014) "Product Information. Impavido (miltefosine)." Paladin Therapeutics Inc
Miltefosine drug interactions
There are 6 drug interactions with miltefosine.
Miltefosine alcohol/food interactions
There is 1 alcohol/food interaction with miltefosine.
Report options
More about miltefosine
- miltefosine consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: anthelmintics
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.